ASX Announcement

24 November 2026

Results of Annual General Meeting

Melbourne, Australia, 24 November 2026: Rhythm Biosciences Ltd (ASX: RHY) ('Rhythm' or the 'Company') advises that all resolutions considered at the Annual General Meeting held today were conducted on a poll.

In accordance with Listing Rule 3.13.2 and section 251AA(1) of the Corporations Act 2001 (Cth), details of the proxies received and votes cast in respect of each resolution are attached.

The result of voting in relation to Resolution 1 (Remuneration Report) constitutes a 'first strike' under section 250U of the Corporations Act (Cth) 2001.

The Board thanks shareholders for their ongoing support.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Sue MacLeman	Non-Executive Chair (Interim)
Maureen Baker	Non-Executive Director
Carl Stubbings	Non-Executive Director
David Atkins	CEO & Managing Director

Results of Meeting

Rhythm Biosciences Limited

Annual General Meeting

Tuesday, 24 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results	
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**	**S250U APPLICABLE**
1 ADOPTION OF REMUNERATION REPORT	P	75,954,911 72.18%	28,257,614 26.85%	72,567	1,012,772 0.96%	81,010,446 74.14%	28,256,743 25.86%	72,567	-	Yes
2 RE-ELECTION OF MS SUE MACLEMAN	P	107,840,729 98.91%	174,428 0.16%	1,303,436	1,012,772 0.93%	112,895,393 99.85%	174,428 0.15%	1,303,436	Carried	n/a
3 ELECTION OF MS MAUREEN BAKER	P	107,773,871 97.78%	1,434,177 1.30%	110,545	1,012,772 0.92%	112,828,535 98.74%	1,434,177 1.26%	110,545	Carried	n/a
4 ELECTION OF MR CARL STUBBINGS	P	107,766,871 98.92%	161,286 0.15%	1,390,436	1,012,772 0.93%	112,821,535 99.86%	161,286 0.14%	1,390,436	Carried	n/a
5 APPROVAL OF 10% PLACEMENT CAPACITY	P	107,461,471 97.44%	1,814,540 1.65%	42,582	1,012,772 0.92%	112,517,006 98.41%	1,813,669 1.59%	42,582	Carried	n/a
6 ADOPTION OF EMPLOYEE INCENTIVE OMNIBUS PLAN	P	97,389,853 92.52%	6,864,694 6.52%	30,545	1,012,772 0.96%	102,445,388 93.72%	6,863,823 6.28%	30,545	Carried	n/a
7A RATIFICATION OF PRIOR ISSUE OF UNDERWRITING AGREEMENT OPTIONS	P	99,916,128 93.94%	5,434,900 5.11%	1,131,091	1,012,772 0.95%	104,971,663 95.08%	5,434,029 4.92%	1,131,091	Carried	n/a
7B RATIFICATION OF PRIOR ISSUE OF UNDERWRITER OPTIONS	P	102,772,602 94.10%	5,434,900 4.98%	1,111,091	1,012,772 0.93%	107,828,137 95.20%	5,434,029 4.80%	1,111,091	Carried	n/a
8 APPROVAL OF ISSUE OF DEFERRED SHARES TO DR DAVID ATKINS	P	97,226,794 92.38%	7,000,753 6.65%	50,545	1,019,772 0.97%	102,289,329 93.60%	6,999,882 6.40%	50,545	Carried	n/a

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results	
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**	**S250U APPLICABLE**
9 APPROVAL OF ISSUE OF OPTIONS TO MS MAUREEN BAKER	P	101,831,535 96.75%	2,403,012 2.28%	50,545	1,012,772 0.96%	106,887,070 97.80%	2,402,141 2.20%	50,545	Carried	n/a
10 APPROVAL OF ISSUE OF OPTIONS TO MR CARL STUBBINGS	P	101,824,535 96.75%	2,403,012 2.28%	57,545	1,012,772 0.96%	106,880,070 97.80%	2,402,141 2.20%	57,545	Carried	n/a
11 APPROVAL OF ISSUE OF OPTIONS TO DR DAVID ATKINS	P	97,226,794 92.39%	7,000,753 6.65%	57,545	1,012,772 0.96%	102,282,329 93.59%	6,999,882 6.41%	57,545	Carried	n/a

